Consultant, Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS)
Assistant Professor of Medicine, Yong Loo Lin School of Medicine, National University of Singapore (NUS)
Adjunct Assistant Professor, Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA
Programme Director, NUHS Medical Oncology Senior Residency Programme
Dr Chee Cheng Ean graduated from University College London (UCL) Medical School, London, UK with a Bachelor of Science (Hons) in Tumour Biology in 2001 and MBBS (Lond) in 2004. She then pursued her post-graduate training in the US by completing her residency in Internal Medicine (2008) and fellowship in Haematology and Oncology (2011) at the Mayo Clinic in Rochester, Minnesota. She was also appointed as Chief Fellow of the Mayo Clinic Haematology/Oncology Fellowship Program and promoted to Assistant Professor of Medicine and Oncology during her time at Mayo Clinic. Dr Chee subsequently joined the Division of Haematology/Oncology at Case Western Reserve University in Cleveland, Ohio, USA as an attending physician and Assistant Professor of Medicine.
Her clinical research portfolio includes a novel biomarker study in colorectal cancer which was awarded institutional and national grant funding. She also developed and was Principal Investigator and national study chair of a Phase I/II US cooperative group clinical trial of a Wee1 inhibitor in pancreas cancer which received full support and endorsement by the Eastern Cooperative Oncology Group (ECOG)-American College of Radiology Imaging Network (ACRIN) and Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI) in the US. Her work in pancreas cancer lead to her appointment as the ECOG representative to the Pancreatic Cancer Task Force of the NCI Gastrointestinal Steering Committee. She has many publications in peer-reviewed journals and has been invited as a journal reviewer in her field.
Dr Chee is a specialist in medical oncology and currently practices as a consultant medical oncologist and clinician scientist at the National University Cancer Institute, Singapore. She is board certified by the American Board of Internal Medicine (ABIM) in Internal Medicine, Medical Oncology and Haematology. Dr Chee’s interests are in cancers of the gastrointestinal (GI) tract which includes colorectal cancer, liver and pancreas cancers, cancers of the biliary tract, stomach and oesophageal cancers. She is also interested in drug development of novel agents and phase I trials.
Education and Fellowships
BSc (Hons), MBBS (Lond), ABIM (Int Med), ABIM (Med Onc), ABIM (Hem)
Awards and Honours
- Mary Hellerstein Junior Career Development Award, Case Western Reserve University, Cleveland, OH, USA (2014)
- Louis Stokes Cleveland Veterans Affairs Medical Research and Foundation Grant, Cleveland, OH, USA (2012)
- Case GI SPORE Career Development Award, Case Western Reserve University, Cleveland, OH, USA (2012)
- Case GI SPORE Pilot Award, Case Western Reserve University, Cleveland, OH, USA (2012)
- Chief Fellow, Haematology/Oncology, Mayo Clinic, Rochester, MN, USA (2010)
- Merit Award, final MBBS exam, University College London Medical School, UK (2004)
- Sir Thomas Lewis Prize in Cardiology, University College London, UK (2004)
- Amulree Elective Scholarship Award, University College London Medical School, UK (2003)
- Bernard Hart Prize in Clinical Neurosciences, University College London, UK (2003)
- Merit Award, Year 3 University College London Medical School, UK (2002)
- Tumour Biology Research Project Prize, University College London, UK (2001)
- Wellcome Trust Research Scholarship, UK (2001)
- American Society of Clinical Oncology
- American College of Physicians
- Gastrointestinal Cancers
- Phase I Clinical Trials
- Chee CE, Meropol NJ. Current Status of Gene Expression Profiling to Assist Decision Making in Stage II Colon Cancer. Oncologist. 2014; 19(7): 704-11.
- Chee CE, Ashrani AA, Marks RS, Petterson TM, Bailey KR, Melton LJ 3rd, Heit JA. Predictors of Venous Thromboembolism Recurrence and Bleeding Among Active Cancer Patients: A Population-Based Cohort Study. Blood. 2014; 123(25): 3972-8.
- Chee CE, Krishnamurthi S, Nock CJ, Meropol NJ, Gibbons J, Fu P, Bokar J, Teston L, O’Brien T, Gudena V, Reese A, Bergman M, Saltzman J, Wright JJ, Dowlati A, Brell JM. Phase II Study of Dasatinib (BMS-354825) in Patients with Metastatic Adenocarcinoma of the Pancreas. Oncologist. 2013; 18(10): 1091-2.
- Yang ZJ, Chee CE, Huang S, Sinicrope FA. The Role of Autophagy in Cancer: Therapeutic Implications. Mol Cancer Ther. 2011; 10(9): 1533-41.
- Yang ZJ, Chee CE, Huang S, Sinicrope FA. Autophagy Modulation for Cancer Therapy. Cancer Biol Ther. 2011; 11(2): 169-76.
- Larsen JT, Chee CE, Lust JA, Greipp PR, Rajkumar SV. Reduction in Plasma Cell Proliferation Following Initial Therapy in Newly Diagnosed Multiple Myeloma Measures Treatment Response and Predicts Improved Survival. Blood. 2011; 118(10): 2702-7.
- Chee CE, Sinicrope FA. Targeted Therapeutic Agents for Colorectal Cancer. Gastroenterol Clin North Am. 2010; 39(3): 601-13.
- Chee CE, Jett JR, Bernath AM, Foster NR, Nelson GD, Molina J, Nikcevich DA, Steen PD, Flynn PJ, Rowland KM. Phase II Trial of Pemetrexed Disodium and Carboplatin in Previously Untreated Extensive Stage Small Cell Lung Cancer, N0423. Cancer. 2010; 116(10): 2382-9.
- Chee CE, Kumar S, Larson DR, Kyle RA, Dispenzieri A, Gertz MA, Colby CL, Rajkumar SV. The Importance of Bone Marrow Examination in Determining Complete Response to Therapy in Patients with Multiple Myeloma. Blood. 2009; 114(13): 2617-8.
- Chee CE, Steensma DP, Wu W, Hanson CA, Tefferi A. Neither Serum Ferritin nor the Number of Red Blood Cell Transfusions Affect Overall Survival in Refractory Anemia with Ringed Sideroblasts. Am J Hematol. 2008; 83(8): 611-3.
Updated as of 23 June 2017